←
Liang Cheng, MD1,135 posts
Liang Cheng, MD avatar✓

Liang Cheng, MD ✓

@LiangChengMD

Professor of Pathology& Surgery(Urology) @BrownUniversity;Vice Chair,Director of Anatomic & Molecular Pathology @BrownPathology;Associate Director @BrownUCancer

◷ Joined June 2020▧ 453 Photos and videos
Liang Cheng, MD avatar
Liang Cheng, MD@LiangChengMD·23 Apr 2025

On this World Book Day, I’m thrilled to announce the release of the Second Edition of Bladder Pathology, following the publication of the first edition in 2012. This fully updated, 880-page reference captures the most recent advances in diagnostic urologic pathology and is now available for purchase: amazon.com/dp/B0DRZ6FB7N This essential volume bridges cutting-edge science with practical, evidence-based guidance for diagnosing and managing bladder diseases across diverse clinical settings. Incorporating the 2022 WHO Classification of Tumours and the most recent AJCC TNM staging, this edition expands on key developments in cancer genomics, molecular pathology, and diagnostic biomarkers. It also offers a deeper focus on therapeutic implications and clinicopathologic correlations, making it an indispensable resource in the era of precision medicine. With over 1,000 high-quality color illustrations, Bladder Pathology provides comprehensive coverage of benign and malignant conditions, congenital anomalies, inflammatory and metaplastic disorders, and the evolving histologic subtypes of bladder cancer.  Designed for practicing pathologists, urologists, oncologists, and trainees, this book delivers a rigorous, up-to-date foundation for accurate diagnosis and personalized patient care. In the age of precision genomics, this second edition highlights the expanding role of molecular pathology in diagnosis, tumor classification, and individualized treatment planning. It reflects the ongoing paradigm shift in urologic pathology - where evidence-based approaches and genomic insights are reshaping clinical practice. With its comprehensive coverage, clarity, clinical relevance, and richly illustrated format, Bladder Pathology is an indispensable resource for navigating the complexity and diversity of bladder disease in contemporary medicine. READ YOUR WAY!

Post attachmentPost attachmentPost attachment
OncoDaily GU avatar
⟳ Liang Cheng, MD retweeted
OncoDaily GU@OncoDailyGU·Nov 16

10 Must-Read Posts in GU Oncology | November 8–14, 2026 This week's selection highlights research and expert perspectives across prostate, bladder, urothelial, and renal cell cancers. Key updates: ▫️ Lynch syndrome and urothelial cancer risk. ▫️ Updated prostate cancer screening recommendations. ▫️ IMPACT UTUC: International consensus on non-metastatic upper tract urothelial carcinoma. ▫️ Tumor microenvironment and immunotherapy resistance in bladder cancer. ▫️ VOLGA: FDA approval of neoadjuvant enfortumab vedotin plus durvalumab, followed by adjuvant durvalumab, in cisplatin-ineligible or refusing patients with MIBC. ▫️ STAMPEDE, ENZARAD, DASL-HiCaP: ADT plus ARPI outcomes in high-risk prostate cancer. ▫️ KEYNOTE-564: Final survival outcomes with adjuvant pembrolizumab in ccRCC. ▫️ Spatial biology and AI-based survival prediction in RCC. ▫️ PROTEUS: Expert commentary on the prostate cancer trial. ▫️ Urinary biomarkers and liquid biopsies in non-muscle-invasive bladder cancer. Takeaway: Ten perspectives on treatment advances, screening, immunotherapy, and biomarkers shaping GU oncology research. @niklas_kluemper @DrShariat @PandolfoSD @tompowles1 @neerajaiims @drenriquegrande @HasanovLab @PaulSargos @LiangChengMD oncodaily.com/genitourinary-… #OncoDaily #GUOncology

Post attachment
Liang Cheng, MD avatar
Liang Cheng, MD@LiangChengMD·Nov 14

“Urinary biomarkers in non-muscle invasive bladder cancer: translating multiplex and genomic liquid biopsies into clinical practice” Great work led by Professor Zhang and colleagues, now published online in NPJ Precision Oncology @Nature_NPJ. Honored to be part of this collaborative work. We review the rapidly evolving landscape of urinary biomarkers and liquid biopsies and their potential to transform the clinical management of bladder cancer. As the field moves beyond conventional cytology and protein assays, RNA panels, DNA mutation and methylation assays, urinary tumor DNA, extracellular vesicles, and emerging multiplex and multi-omic platforms are creating new opportunities for precision-guided care. These approaches may improve hematuria triage, detect recurrence and minimal residual disease, predict treatment response, and enable more personalized surveillance. High-negative-predictive-value assays may also help safely reduce the burden of repeated cystoscopy in appropriately selected patients while maintaining oncologic vigilance. The major challenge is now translation into clinical practice. This will require standardized urine collection and processing, reproducible assays, clinically meaningful decision thresholds, prospective biomarker-guided trials, and demonstration of cost-effectiveness. Looking ahead, the integration of genomic liquid biopsy, extracellular vesicles, multi-omics, and AI may provide a “molecular safety net” for more precise, less invasive, and patient-centered bladder cancer management. Full article is available for free download: nature.com/articles/s41698-0…

Post attachmentPost attachmentPost attachment
Liang Cheng, MD avatar
Liang Cheng, MD@LiangChengMD·Nov 7

Published in the October 2026 issue of European Urology @EUPlatinum (Impact Factor: 29), this collaborative work was led by Roger Li @UrogerliMD, Can Aydogdu @CanDAydogdu, Laura Bukavina @LauraBukavinaMD A must-read for anyone interested in bladder cancer! Great honor to be part of this work.  @UroDocAsh @AndreaNecchi @apolo_andrea @SpiessPhilippe This comprehensive review provides an integrated overview of the pathology, molecular characteristics, and clinical management of major bladder cancer subtypes, including squamous, adenocarcinoma/glandular, micropapillary, sarcomatoid, plasmacytoid, nested, and small cell neuroendocrine carcinoma. These tumors are biologically heterogeneous, often clinically aggressive, and frequently understaged on transurethral resection, supporting consideration of early radical cystectomy in selected high-risk patients.   Importantly, treatment response varies substantially by histology. Small cell neuroendocrine carcinoma demonstrates the clearest benefit from platinum/etoposide-based chemotherapy, while other subtypes show variable responses to conventional systemic therapies. Molecular profiling reveals potentially actionable alterations, including ERBB2 in micropapillary carcinoma, CDH1 loss in plasmacytoid carcinoma, FGFR3 alterations in nested carcinoma, and TP53/RB1 alterations in small cell carcinoma. Emerging evidence also supports potential roles for immune checkpoint inhibitors and antibody-drug conjugates.   We emphasizes that variant bladder cancers should not be managed using a uniform approach. Accurate histologic classification, quantification of subtype components, and molecular profiling are increasingly important for personalized treatment and future subtype-specific clinical trials.   Full article available at authors.elsevier.com/c/1nL8w…

Post attachmentPost attachmentPost attachment
Liang Cheng, MD avatar
Liang Cheng, MD@LiangChengMD·Nov 4

The December 2026 issue of Histopathology@Histo_Journal is out! Honored to have had the opportunity to collaborate and contribute three articles to this issue. Congratulations to all the authors on their excellent work! 🔹 Perivascular epithelioid cell tumours of the genitourinary tract: clinicopathological features and molecular landscape pubmed.ncbi.nlm.nih.gov/4236…
doi.org/10.1111/his.70204 🔹 Histological assessment of treatment effect in lymph node-positive breast cancer after neoadjuvant chemotherapy pubmed.ncbi.nlm.nih.gov/4254…
doi.org/10.1111/his.70256 🔹 Spermatocytic tumours containing an intratubular component: a multi-institutional study emphasizing diagnostic pitfall with germ cell neoplasia in situ pubmed.ncbi.nlm.nih.gov/4254… doi.org/10.1111/his.70259

Post attachmentPost attachmentPost attachmentPost attachment
Liang Cheng, MD avatar
Liang Cheng, MD@LiangChengMD·Oct 30

Very happy to share newest online publication in JAMA Oncology @JAMAOnc, "FGFR Alterations in Bladder Cancer- From Molecular Pathogenesis to Precision Oncology," written by Dr. Katrina Collins @katcollmd In this review, we examine how FGFR biology is reshaping the molecular classification and precision management of patients with bladder cancer. We highlight the central role of FGFR3 alterations and the fast-growing range of molecular biomarker testing at every stage of disease. We discuss comprehensive genomic profiling, liquid biopsy (including urine-based molecular testing), and emerging molecular residual disease (MRD) assessment. We also cover how each is used in diagnosis, treatment selection, surveillance, and disease monitoring. On the therapeutic front, erdafitinib has established FGFR-directed precision therapy in advanced urothelial carcinoma. Combination approaches, intravesical FGFR-directed treatments, and next-generation FGFR3-selective inhibitors are extending this strategy into new clinical settings. Emerging technologies, including AI-assisted histopathology and integrated multi-omic biomarkers, may further refine patient selection. Read the full article: doi.org/10.1001/jamaoncol.20…

Post attachmentPost attachment
Liang Cheng, MD avatar
Liang Cheng, MD@LiangChengMD·Oct 23

Excited to share our newly published article in Nature Reviews Urology @NatRevUrol, “Rare Prostate Cancer Histologies: Detection, Characteristics and Treatment,” led by Drs. Spiess and Melão. @SpiessPhilippe @UrogerliMD @katcollmd @neerajaiims @PGrivasMDPhD @AndreaNecchi This comprehensive review highlights the diagnostic, molecular, and clinical features of both common and rare prostate cancer histologic subtypes, including mucinous, intraductal, ductal, neuroendocrine, sarcomatoid, and adenoid cystic (basal cell) carcinomas. We also explore advances in pathology, imaging, molecular profiling, immunotherapy and precision oncology, while addressing important unmet clinical needs and future research directions.   Full article available: nature.com/articles/s41585-0…

Post attachmentPost attachment
Liang Cheng, MD avatar
Liang Cheng, MD@LiangChengMD·Oct 21

PYGO2 deletion links enhanced antitumour immunity to delayed castration resistance in prostate cancer!   Congratulations to Prof. Xin Lu and his team on the publication of this important study in Cancer Letters@TheCancerLetter (journal impact factor, 11.8). Great honor to be part of this work.   In this study, Prof. Lu and colleagues identify PYGO2, a chromatin regulator, as a potential therapeutic target for addressing both immune exclusion and resistance to androgen deprivation in prostate cancer. Using genetically engineered mouse models, we demonstrate that Pygo2 deletion restores androgen receptor signalling, increases sensitivity to surgical castration, and delays the development of castration-resistant disease.   Mechanistically, Pygo2 loss promotes DNA damage and activates STING–interferon signalling, thereby enhancing antitumour immune responses. Silencing STING attenuates immune cell recruitment and tumour control, highlighting the importance of this pathway. Notably, combining Pygo2 deletion with castration, the CXCR1/2 inhibitor SX-682, and dual PD-1/CTLA-4 blockade achieves durable disease control in these preclinical models.   These findings highlight PYGO2 as a promising therapeutic target for advanced prostate cancer and suggest that combining androgen deprivation with targeted immune activation may help overcome mechanisms of treatment resistance. The development of selective PYGO2 inhibitors represents an important next step towards clinical translation.   Importantly, this study provides a compelling rationale for investigating PYGO2-targeted strategies to transform immunologically quiescent prostate tumours into more immunologically active environments that are susceptible to combination therapy.   Read the full article: doi.org/10.1016/j.canlet.202…

Post attachmentPost attachmentPost attachment
Liang Cheng, MD avatar
Liang Cheng, MD@LiangChengMD·Oct 17

What a memorable XXXVI International Congress of the International Academy of Pathology (IAP 2026) in Fukuoka, Japan!  It was a wonderful opportunity to reconnect with colleagues and friends from around the world, exchange ideas, strengthen international collaborations, and celebrate the latest advances in pathology.   The International Society of Urological Pathology (ISUP) @IntSocUropath also hosted a highly successful Companion Meeting, attracting a large and enthusiastic audience. Our distinguished speakers delivered outstanding presentations highlighting recent advances in urologic surgical pathology.   Special thanks to the IAP 2026 organizers, the Japanese Society of Pathology, and the local organizing committee for their exceptional organization, warm hospitality, and tremendous efforts in making this international congress such a resounding success!

Post attachmentPost attachmentPost attachmentPost attachment
Liang Cheng, MD avatar
Liang Cheng, MD@LiangChengMD·Oct 10

The first-ever WHO GU Editorial Board Meeting hosted in Beijing at Peking Union Medical College (PUMC) was a tremendous success, bringing together leading experts from around the world to help shape the future of genitourinary tumor classification.   Big congratulations and heartfelt thanks to our wonderful local organizer, Professor Liang Zhiyong, and the entire PUMC team for their outstanding organization, incredibly warm hospitality, and friendship. They made this landmark meeting truly memorable and unforgettable.   We now look forward with great excitement to the WHO Classification of Urinary and Male Genital Tumours, 6th Edition (WHO URO6), with further refinement and standardization of tumor classification, incorporation of important scientific advances, and recognition of many new tumor entities that our group has contributed.   A remarkable meeting, wonderful colleagues, and an exciting new chapter for GU Pathology worldwide. Grateful and honored to be part of this historic moment!

Post attachmentPost attachmentPost attachmentPost attachment